Monitor the commercial progress of ampreloxetine, as CVR payouts depend on monetization and first commercial sales. Also watch YUPELRI profit-share cash flows, as 75% is assigned to service the $350M OMERS notes, which could constrain cash available for other operations.
Drugs in focus
ZYME drug pipeline →YUPELRI
● Neutral Named in this 8-K/A- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially marketed (FDA approved November 2018; China NMPA approved June 2025).
- Next catalyst
- None dated
What to watchYUPELRI is now a cash-flow asset within Zymeworks (ZYME), which reported Q3 2026 earnings today (Nov 9) with revenue of $256.5M, beating consensus, and raised full-year guidance to $337M-$351M. The next catalyst to watch is Zymeworks' Q4 2026 report in early 2027, which will show the first full quarter of YUPELRI contribution under Zymeworks ownership. No binary regulatory catalyst is pending for YUPELRI itself.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $31.46entry
- T+1 · 6d ago −7.60%α −8.92% · $29.07
- T+4 · todayOpen
- T+5 · in 9h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
This 8-K/A amends the original 8-K to provide historical financial statements of Theravance Biopharma and unaudited pro forma combined financials for Zymeworks following its acquisition of Theravance, which closed on September 23, 2026. Theravance shareholders received $17.00 per share in cash plus contingent value rights tied to ampreloxetine. The cash consideration was partly financed via $350 million in non-recourse notes from OMERS Life Sciences, secured by YUPELRI profit-share cash flows. Pro forma combined net income for the nine months ended September 30, 2026 was $11.8 million ($0.16 basic EPS), compared to a pro forma net loss of $43.7 million for FY 2025.
Key Facts
- Zymeworks completed acquisition of Theravance on September 23, 2026, with Theravance becoming a wholly owned subsidiary.
- Theravance shareholders received $17.00 per share in cash plus one contingent value right (CVR) per share.
- CVRs entitle holders to 80% of net proceeds from ampreloxetine monetization, $50M upon first commercial sale in specified countries, and 10% of net sales.
- Total consideration for outstanding shares and equity awards was $915.6 million, net of $355.2 million cash acquired, resulting in net consideration of $560.4 million.
- The cash portion was financed with $350 million in non-recourse notes from OMERS Life Sciences, bearing 8.25% interest and maturing December 31, 2036.
- 75% of YUPELRI profit-share cash flows are assigned to service the OMERS notes.
- Preliminary purchase price allocation includes $415.4 million for YUPELRI product rights intangible and $104.4 million in goodwill.
- Pro forma combined revenue for nine months ended September 30, 2026 was $321.2 million; pro forma net income was $11.8 million ($0.16 basic EPS).
- Pro forma combined revenue for FY 2025 was $213.4 million; pro forma net loss was $43.7 million ($0.58 basic loss per share).
- No Zymeworks common shares were issued as consideration; basic share count unchanged.
Financial Impact
Total consideration of $915.6 million for Theravance shares and equity awards, net of $355.2 million cash acquired, resulting in net consideration of $560.4 million. Pro forma combined net income of $11.8 million for nine months ended September 30, 2026.
Risk Factors
- The $350M OMERS notes are non-recourse but secured by YUPELRI assets; 75% of YUPELRI profit-share cash flows are assigned to debt service, reducing cash available for other uses.
- CVRs were assigned no fair value due to remote likelihood of future events; ampreloxetine commercial success is uncertain.
- Preliminary purchase price allocation is subject to change and could materially impact future amortization and goodwill.
- Pro forma financials do not reflect potential restructuring, integration costs, or synergies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K/A Filing (Primary) | 0001193125-26-453730 |
| Document: d79244d8ka.htm | 0001193125-26-453730 |
| Document: d79244dex231.htm | 0001193125-26-453730 |
| Document: 0001193125-26-453730-index-headers.html | 0001193125-26-453730 |
| Document: 0001193125-26-453730-index.html | 0001193125-26-453730 |
| Document: 0001193125-26-453730.txt | 0001193125-26-453730 |
Track record
25 reports on ZYME
6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +16.72% at T+60 after the Jun 14, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 16, 2026today 8-K Neutral 4/10 Entry price pending
- Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $26.24 Now $26.45 +0.80% settles Dec 14
- Nov 9, 20267d ago 8-K/A Neutral 5/10 Viewing Entry $31.46 Now $26.45 −15.92% settles Dec 9
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $31.46 Now $26.45 −15.92% settles Dec 9
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $30.94 Now $26.45 −14.51% settles Dec 3
- Oct 26, 202621d ago DEFA14A Neutral 2/10 Entry $28.85 Now $26.45 −8.32% settles Nov 24
- Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $28.85 Now $26.45 −8.32% settles Nov 24
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $28.22 Now $26.45 −6.27% settles Nov 20
- Oct 15, 20264w ago Press Release Neutral 1/10 Entry $25.75 to $29.07 Now $26.45 +2.72% ▲ +12.89% +14.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers